Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...
Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.
Vertanical reports Phase 3 success for VER-01, a non-opioid cannabis-based painkiller for chronic back pain. Drug could be approved in Europe by July, per founder Clemens Fischer.
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
This law is a great step forward, especially with the recent news that the FDA has approved the use of a non-opioid painkiller. Congress can and should take further action by passing the ...
To read more letters to the editor, go to oregonlive.com/opinion.
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results